We are live on ! Find out more
LMR Partners

LMR Partners Portfolio holdings

AUM $32.6B Turnover 45.75%
1-Year Est. Return 45.61%
 

LMR Partners is a British multi-strategy investment firm named after its three founders, Ben Levine, Andrew Manuel and Stefan Renold, whose surname initials spell LMR. All three had been traders at UBS and Goldman Sachs, and Paloma Partners provided seed money before the firm began trading in 2010. Manuel left in 2015 and launched Ixworth Capital, his own global macro hedge fund. The firm focuses on global macro and event-driven strategies, mixing computer-model trading with trades chosen by its portfolio managers.

This Fund
S&P 500
This Quarter Est. Return
+4.46%
1 Year Est. Return
+45.61%
3 Year Est. Return
+238.3%
5 Year Est. Return
+283.63%
10 Year Est. Return
+733.38%
AUM
$32.6B
AUM Growth
+$5.8B
Cap. Flow
-$2.24B
Cap. Flow %
-6.88%
Top 10 Hldgs %
23.21%
Holding
1,998
New
512
Increased
354
Reduced
303
Closed
402
Avg Time Held Equity + Options
0.7 years
Top 10 Avg Time Held Equity + Options
0.2 years
Top 20 Avg Time Held Equity + Options
0.4 years
Avg Time Held Equity only
0.7 years
Top 10 Avg Time Held Equity only
0.5 years
Top 20 Avg Time Held Equity only
0.6 years

Top Buys

Rank Stock Value
1
LNTH icon
Lantheus
LNTH
+$215M
2
NVS icon
Novartis
NVS
+$116M
3
LITE icon
Lumentum
LITE
+$91.8M
4
MDT icon
Medtronic
MDT
+$90.8M
5
SHOP icon
Shopify
SHOP
+$88.5M

Sector Composition

Rank Sector Weight
1 Miscellaneous 74.57%
2 Technology 7.25%
3 Healthcare 5.19%
4 Communication Services 3.16%
5 Financials 2.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
INTU icon
1251
Intuit
INTU
$72.3B
$334K ﹤0.01%
1,212
-14,939
-92% -$4.69M
2025 Q4
3 quarters
PNW icon
1252
Pinnacle West Capital
PNW
$12.3B
$333K ﹤0.01%
+3,577
New +$359K
2026 Q3
0 quarters
ATRC icon
1253
AtriCure
ATRC
$2.82B
$332K ﹤0.01%
+5,900
New +$266K
2026 Q3
0 quarters
REPL icon
1254
CALL
Replimune Group
REPL
$1.81B
$331K ﹤0.01%
+25,000
New +$316K
2026 Q3
0 quarters
SCHL icon
1255
CALL
Scholastic
SCHL
$687M
$331K ﹤0.01%
+9,400
New +$381K
2026 Q3
0 quarters
XIIIW
1256
Churchill Capital Corp XIII Warrants
XIIIW
$330K ﹤0.01%
+200,000
New +$418K
2026 Q3
0 quarters
OABIW icon
1257
OmniAb Warrant
OABIW
$330K ﹤0.01%
897,392
– –
2024 Q4
7 quarters
CL icon
1258
Colgate-Palmolive
CL
$78.5B
$330K ﹤0.01%
3,862
-3,579
-48% -$324K
2026 Q2
1 quarter
GILD icon
1259
Gilead Sciences
GILD
$206B
$329K ﹤0.01%
2,209
-13,682
-86% -$1.92M
2026 Q2
1 quarter
KEYS icon
1260
Keysight
KEYS
$44.5B
$322K ﹤0.01%
884
-40,018
-98% -$13.2M
2025 Q3
4 quarters
CAPR icon
1261
PUT
Capricor Therapeutics
CAPR
$441M
$319K ﹤0.01%
33,700
+10,500
+45% +$116K
2026 Q2
1 quarter
DSACW icon
1262
Daedalus Special Acquisition Corp Warrant
DSACW
$315K ﹤0.01%
+508,068
New +$323K
2026 Q3
0 quarters
THC icon
1263
Tenet Healthcare
THC
$20.9B
$314K ﹤0.01%
+1,229
New +$302K
2026 Q3
0 quarters
GIS icon
1264
General Mills
GIS
$19.1B
$311K ﹤0.01%
9,684
+3,434
+55% +$128K
2026 Q2
1 quarter
CPB icon
1265
Campbell's
CPB
$7.11B
$311K ﹤0.01%
+15,679
New +$348K
2026 Q3
0 quarters
WEC icon
1266
WEC Energy
WEC
$38.5B
$309K ﹤0.01%
3,066
-635
-17% -$69.1K
2025 Q2
5 quarters
EQH icon
1267
Equitable Holdings
EQH
$13.4B
$307K ﹤0.01%
5,994
-80,882
-93% -$4.07M
2026 Q2
1 quarter
OCUL icon
1268
PUT
Ocular Therapeutix
OCUL
$1.22B
$307K ﹤0.01%
+40,000
New +$392K
2026 Q3
0 quarters
TACHW icon
1269
Titan Acquisition Corp Warrants
TACHW
$305K ﹤0.01%
550,000
– –
2025 Q2
5 quarters
M icon
1270
Macy's
M
$6.05B
$303K ﹤0.01%
+13,292
New +$309K
2026 Q3
0 quarters
TAP icon
1271
Molson Coors Class B
TAP
$7.27B
$300K ﹤0.01%
+8,222
New +$331K
2026 Q3
0 quarters
OSS icon
1272
PUT
One Stop Systems
OSS
$100M
$298K ﹤0.01%
34,100
– –
2026 Q2
1 quarter
PNC icon
1273
PNC Financial Services
PNC
$84.7B
$297K ﹤0.01%
+1,336
New +$327K
2026 Q3
0 quarters
DASH icon
1274
DoorDash
DASH
$66.5B
$296K ﹤0.01%
1,614
-16,386
-91% -$3.31M
2025 Q2
5 quarters
ISRG icon
1275
Intuitive Surgical
ISRG
$138B
$295K ﹤0.01%
725
-5,685
-89% -$2.17M
2026 Q1
2 quarters

Similar funds

LMR Partners's Q3 2026 Portfolio in Review

As of Q3 2026, LMR Partners held 1,998 positions worth $32.6B, up 22% from $26.8B the previous quarter. Its ten largest holdings account for 23% of the portfolio.

LMR Partners withdrew a net $2.24B in Q3 2026, closing 402 positions and reducing 303 holdings. Its most notable exit was Chart Industries, an estimated $109M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 75% of assets, up from 71% a quarter earlier, followed by Technology and Healthcare.

Against the trend, LMR Partners opened a new position in Lantheus worth $210M.

  • LMR Partners's largest Q3 2026 buy was Lantheus: 2,108,000 shares worth $210M.
  • LMR Partners added most to Novartis in Q3 2026, an estimated $116M increase.
  • LMR Partners's biggest Q3 2026 reduction was iShares Core S&P 500 ETF, cutting an estimated $632M.
  • LMR Partners fully exited Chart Industries in Q3 2026, selling an estimated $109M.
  • LMR Partners's ten largest holdings make up 23% of its $32.6B portfolio in Q3 2026.
  • LMR Partners opened 512 new positions and closed 402 in Q3 2026.
  • LMR Partners's portfolio value rose 22% quarter-over-quarter to $32.6B.

Based on LMR Partners's 13F filing for Q3 2026, filed 16 Nov 2026.